---
title: "Canaccord Genuity Remains a Buy on Rani Therapeutics Holdings (RANI)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295802490.md"
description: "Canaccord Genuity analyst Edward Nash maintains a Buy rating on Rani Therapeutics Holdings (RANI) with a $5.00 price target, despite shares closing at $0.80. Nash, a top-rated healthcare sector analyst, covers RANI alongside Travere and Corcept. The broader analyst consensus for Rani remains a Strong Buy, with an average price target of $7.50."
datetime: "2026-08-13T12:45:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295802490.md)
  - [en](https://longbridge.com/en/news/295802490.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295802490.md)
generator: "portal-rs"
---

# Canaccord Genuity Remains a Buy on Rani Therapeutics Holdings (RANI)

In a report released yesterday, Edward Nash from Canaccord Genuity maintained a Buy rating on Rani Therapeutics Holdings, with a price target of $5.00. The company’s shares closed yesterday at $0.80.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Nash is a 5-star analyst with an average return of 31.4% and a 55.78% success rate. Nash covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Rani Therapeutics Holdings, and Corcept Therapeutics.

Currently, the analyst consensus on Rani Therapeutics Holdings is a Strong Buy with an average price target of $7.50.

### Related Stocks

- [RANI.US](https://longbridge.com/en/quote/RANI.US.md)
- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [CORT.US](https://longbridge.com/en/quote/CORT.US.md)

## Related News & Research

- [Top Insider Makes Bold Move on Rani Therapeutics Stock](https://longbridge.com/en/news/293691544.md)
- [Rani Therapeutics to present at Canaccord Genuity Annual Growth Conference](https://longbridge.com/en/news/295403455.md)
- [This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/296231890.md)
- [Canaccord Genuity Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)](https://longbridge.com/en/news/295789301.md)
- [HC Wainwright Issues Pessimistic Forecast for RANI Earnings](https://longbridge.com/en/news/296899389.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**